Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marina Bacac

Showing results (31-40 of 79) with videos related to

Pageof 8
Sort By:
Oncoimmunology|February 21, 2022
Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophilsGabrielle Leclercq, Llucia Alberti Servera, Sabrina Danilin, et al.
Molecular Cancer Therapeutics|December 10, 2020
Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems ModelingArthur J Van De Vyver, Tina Weinzierl, Miro J Eigenmann, et al.
Antibodies (Basel, Switzerland)|November 24, 2025
CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCBChristina Claus, Claudia Ferrara-Koller, Johannes Sam, et al.
Blood|October 12, 2023
Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trialDespoina Papazoglou, Xin Victoria Wang, Tait D Shanafelt, et al.
Pharmaceutics|December 28, 2021
Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial FluidMiro Julian Eigenmann, Tine Veronica Karlsen, Marek Wagner, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 13, 2016
Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCBSherri Dudal, Heather Hinton, Anna M Giusti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2016
In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor KillingSteffi Lehmann, Ramanil Perera, Hans-Peter Grimm, et al.
Journal for Immunotherapy of Cancer|July 30, 2021
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodiesGabrielle Leclercq, Hélène Haegel, Anneliese Schneider, et al.
Frontiers in Oncology|December 17, 2020
Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor ActivityJohannes Sam, Sara Colombetti, Tanja Fauti, et al.
Cell Reports|October 19, 2022
The target antigen determines the mechanism of acquired resistance to T cell-based therapiesAlex Martínez-Sabadell, Beatriz Morancho, Irene Rius Ruiz, et al.
Pageof 8

Showing results (31-40 of 79) with videos related to

Sort By:
Pageof 8
Oncoimmunology|February 21, 2022
Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophilsGabrielle Leclercq, Llucia Alberti Servera, Sabrina Danilin, et al.
Molecular Cancer Therapeutics|December 10, 2020
Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems ModelingArthur J Van De Vyver, Tina Weinzierl, Miro J Eigenmann, et al.
Antibodies (Basel, Switzerland)|November 24, 2025
CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCBChristina Claus, Claudia Ferrara-Koller, Johannes Sam, et al.
Blood|October 12, 2023
Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trialDespoina Papazoglou, Xin Victoria Wang, Tait D Shanafelt, et al.
Pharmaceutics|December 28, 2021
Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial FluidMiro Julian Eigenmann, Tine Veronica Karlsen, Marek Wagner, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 13, 2016
Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCBSherri Dudal, Heather Hinton, Anna M Giusti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2016
In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor KillingSteffi Lehmann, Ramanil Perera, Hans-Peter Grimm, et al.
Journal for Immunotherapy of Cancer|July 30, 2021
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodiesGabrielle Leclercq, Hélène Haegel, Anneliese Schneider, et al.
Frontiers in Oncology|December 17, 2020
Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor ActivityJohannes Sam, Sara Colombetti, Tanja Fauti, et al.
Cell Reports|October 19, 2022
The target antigen determines the mechanism of acquired resistance to T cell-based therapiesAlex Martínez-Sabadell, Beatriz Morancho, Irene Rius Ruiz, et al.
Pageof 8